Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2026)

Aurinia Pharmaceuticals has reported EBT Margin for 8 years, with the latest figure at 56.53% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 1755.0% year-over-year to 56.53%; the trailing twelve-month figure through Mar 2026 stood at 44.83% (up 2793.0% YoY), and the FY2025 full-year result was 40.33%, up 3716.0% from the prior year.
• EBT Margin for Q1 2026 stood at 56.53%, up from 46.28% in the prior quarter.
• The five-year high for EBT Margin was 56.53% in Q1 2026, with the low at 173.97% in Q1 2022.
• Historically, EBT Margin has averaged 21.55% across 5 years, with a median of 14.41% in 2022.
• Annual changes were most pronounced in 2022 — EBT Margin jumped 533709 bps — and 2023, when it sank 971 bps.
• Aurinia Pharmaceuticals' EBT Margin stood at 88.59% in 2022, then soared by 34 bps to 58.58% in 2023, then surged by 103 bps to 1.96% in 2024, then soared by 2262 bps to 46.28% in 2025, then gained by 22 bps to 56.53% in 2026.
• The last three EBT Margin figures came in at 56.53% (Q1 2026), 46.28% (Q4 2025), and 43.5% (Q3 2025), per Business Quant data.